Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
ClouDr Group's Enterprise Value for the quarter that ended in Dec. 2025 was €45.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ClouDr Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-115.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ClouDr Group EV-to-EBIT Related Terms
ClouDr Group EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for ClouDr Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, ClouDr Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ClouDr Group EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, ClouDr Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where ClouDr Group's EV-to-EBIT falls into.
ClouDr Group's current Enterprise Value is €12.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ClouDr Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-115.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ClouDr Group (FRA:H3L) has a EV-to-EBIT of -0.10 as of Aug. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ClouDr Group and its competitors. According to the industry distribution chart, ClouDr Group ranks #999999 out of 97 companies in the Medical Distribution industry.
Is ClouDr Group's EV-to-EBIT too high?
ClouDr Group's current EV-to-EBIT is -0.10. Based on the distribution chart, ClouDr Group ranks #999999 out of 97 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, ClouDr Group has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does ClouDr Group's EV-to-EBIT compare to MCK and COR?
According to the Medical Distribution industry distribution chart, ClouDr Group ranks #999999 out of 97 companies for EV-to-EBIT. This places ClouDr Group in the lower half of its industry. The industry median EV-to-EBIT is 12.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 12.21, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ClouDr Group and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 12.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ClouDr Group's current EV-to-EBIT is -0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClouDr Group stock overvalued right now?
ClouDr Group (FRA:H3L) has a current EV-to-EBIT of -0.10. The stock's GF Value™ is €0.08, compared to a current price of €0.05 — trading 36.9% below its estimated fair value. The current EV-to-EBIT is -0.10. ClouDr Group's overall GF Score™ is 48/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For ClouDr Group (FRA:H3L), the current EV-to-EBIT is -0.10 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ClouDr Group (FRA:H3L) Overvalued in 2026?
Based on GuruFocus' analysis, ClouDr Group stock appears to be undervalued.
The current stock price of €0.05 is trading 36.9% below its estimated GF Value™ of €0.08.
Key valuation signals for FRA:H3L:
EV-to-EBIT: -0.10
GF Value™: €0.08 vs. price of €0.05 (36.9% below fair value)
No single metric tells the full story. See the FRA:H3L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. The company's in-hospital solution consists of sales of medical devices, consumables, and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies, and the out-of-hospital solution connects doctors and patients, and provides high-quality and trustworthy medical services through the AI vertical model ClouD GPT. The company generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
48GF Score
Get the complete analysis for FRA:H3L
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:H3L has been successfully added to your 
